Klivira
Request demo

Navigating Humana Tysabri Prior Authorization

For specialized therapies like Tysabri, efficient **Humana Tysabri prior authorization** is critical to patient access and revenue integrity. Klivira automates the complex requirements for this high-volume medication.

Revenue cycle leaders and prior authorization coordinators face unique challenges with high-cost specialty medications. Understanding payer-specific nuances for drugs like Tysabri under Humana's various plans is key to minimizing delays and denials, ensuring timely patient care.

Tysabri: A High-Volume Prior Authorization Target

Tysabri (natalizumab) is an alpha-4 integrin inhibitor indicated for relapsing forms of multiple sclerosis (MS) and moderately to severely active Crohn's disease. As a high-efficacy specialty medication, it consistently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans, necessitating detailed clinical documentation and adherence to specific criteria.

Humana's Prior Authorization Channels for Tysabri

Given Tysabri's typical administration as an intravenous infusion, submissions for Humana members generally route through the medical benefit. Klivira integrates directly with Humana's primary digital channels to facilitate efficient prior authorization.

Key Submission Pathways for Humana Tysabri PA

  • **Availity Essentials Portal:** Humana leverages Availity Essentials as a primary provider portal for medical PA initiation, eligibility verification, and document submission for Medicare Advantage and commercial plans.
  • **X12 278 Transactions:** For high-volume medical benefit PAs, X12 278 transactions are accepted via clearinghouses, supporting a structured electronic exchange of authorization requests.
  • **CenterWell Specialty Pharmacy:** While Tysabri is typically medical benefit, CenterWell Specialty Pharmacy manages specialty injectables and complex medications on the pharmacy benefit; confirm specific policy for any self-administered forms.
  • **ePA via Da Vinci Project & Other Channels:** Humana participates in the HL7 Da Vinci Project, signaling future-state electronic PA capabilities. Existing medical ePA may vary by procedure category.

Navigating Humana's Coverage Policies and Criteria for Tysabri

Humana publishes medical policies and coverage determinations on its provider site, which outline specific criteria for Tysabri approval. For Medicare Advantage members, these policies must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), ensuring consistency with Original Medicare's coverage rules.

Common Denial Reasons and Appeal Pathways for Tysabri with Humana

Denials for Tysabri PA from Humana often stem from insufficient documentation, failure to meet medical necessity criteria, or non-adherence to step therapy protocols. For Medicare Advantage members, the appeal process follows a five-level structure mandated by CMS, beginning with reconsideration and progressing through independent review entities (IREs) and administrative law judges (ALJs).

Frequently asked questions

How does Klivira handle Humana's Availity portal requirements for Tysabri PA?

Klivira's platform integrates with Availity Essentials, automating the data entry, document upload, and status tracking for Tysabri prior authorizations. This reduces manual effort and ensures submissions meet Humana's portal-specific requirements, streamlining the workflow for your PA coordinators.

What are the typical turnaround times for Tysabri prior authorizations with Humana?

For Medicare Advantage plans, Humana is an impacted payer under CMS-0057-F, which mandates a 7-calendar-day standard decision timeframe and 72 hours for expedited requests. Klivira helps monitor these timelines and provides real-time status updates to proactively manage expectations.

Does Humana have step therapy requirements for Tysabri?

Yes, Humana's medical policies for Tysabri, particularly for MS and Crohn's disease, often include step therapy requirements or specific criteria regarding prior treatment failures. Klivira's system helps identify these requirements and ensures the necessary clinical documentation is included in the initial submission.

How does Klivira ensure compliance with CMS-0057-F for Humana Tysabri PAs?

Klivira's platform is designed to align with the principles of CMS-0057-F, supporting electronic PA submission via X12 278 and future-state API connectivity. We facilitate the structured data exchange and real-time status updates required to meet the evolving regulatory landscape for Medicare Advantage prior authorizations.

What documentation is typically needed for a Tysabri prior authorization with Humana?

Common documentation includes confirmed diagnosis (e.g., MRI reports for MS, endoscopy for Crohn's), physician notes detailing disease severity and progression, history of prior therapies and their outcomes, and evidence of meeting Humana's specific medical necessity criteria for Tysabri.

Related coverage

Other tysabri prior authorization by payer

Other tysabri prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo